Koninklijke Philips NV ADR Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
5.6%projected annual EPS growth
Analyst Coverage
5analysts covering
FY Revenue (est.)
$21Bnext fiscal year
FY EPS (est.)
$2.07next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 3 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Comparable Sales Growth Quarterly400.0%Target: 3% to 4.5%
Adjusted EBITA Margin (Underlying) Quarterly1,220.0%Target: 12.5% to 13.0%
Free Cash Flow (Reported) Quarterly222MTarget: EUR 1.5 billion to 1.7 billion
Watch Items
- China Healthcare Market Procurement and Subdued Hospital InvestmentTrigger: Prolonged decline in Diagnosis & Treatment order intake in Growth geographiesAction: Re-evaluate geographic mix and shift focus to high-growth mature markets or alternative growth regions like India.
- US Tariff Refund and Net Tariff HeadwindsTrigger: Changes in US trade policy or tariff structures impacting the 1% margin benefitAction: Adjust full-year reported Adjusted EBITA margin guidance and reassess supply chain localization.
- Philips Respironics-Related Legal ProceedingsTrigger: New developments or financial penalties from the US Department of Justice or State Attorneys GeneralAction: Update risk models, adjust cash flow projections, and evaluate impact on capital allocation.
Research as of 2 Sep 2026